Technical Analysis for CRIS - Curis, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -2.37% | |
| Wide Bands | Range Expansion | -2.37% | |
| Down 3 Days in a Row | Weakness | -2.37% | |
| New 52 Week Closing Low | Bearish | -2.63% |
| Alert | Time |
|---|---|
| Up 1% | about 21 hours ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Possible NR7 | 1 day ago |
| Up 1% | 2 days ago |
| 2x Volume Pace | 2 days ago |
Get a Trading Assistant
- Earnings date: 11/14/2024
Curis, Inc. Description
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Drugs Surgery Drug Discovery Breast Cancer Lymphoma Non Small Cell Lung Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Multiple Myeloma Lung Cancer Cancer Cell Protein Kinase Inhibitor Carcinoma Cancer Therapeutics Hematological Cancers Phosphoinositide 3 Kinase Inhibitor Advanced Non Small Cell Lung Cancer Refractory Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.49 |
| 52 Week Low | 3.51 |
| Average Volume | 49,851 |
| 200-Day Moving Average | 8.44 |
| 50-Day Moving Average | 4.94 |
| 20-Day Moving Average | 4.30 |
| 10-Day Moving Average | 4.04 |
| Average True Range | 0.37 |
| RSI (14) | 26.47 |
| ADX | 19.23 |
| +DI | 12.01 |
| -DI | 26.85 |
| Chandelier Exit (Long, 3 ATRs) | 4.35 |
| Chandelier Exit (Short, 3 ATRs) | 4.61 |
| Upper Bollinger Bands | 5.08 |
| Lower Bollinger Band | 3.51 |
| Percent B (%b) | 0.12 |
| BandWidth | 36.52 |
| MACD Line | -0.34 |
| MACD Signal Line | -0.30 |
| MACD Histogram | -0.0386 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.14 | ||||
| Resistance 3 (R3) | 4.15 | 4.02 | 4.06 | ||
| Resistance 2 (R2) | 4.02 | 3.91 | 4.01 | 4.04 | |
| Resistance 1 (R1) | 3.86 | 3.84 | 3.80 | 3.85 | 4.01 |
| Pivot Point | 3.73 | 3.73 | 3.70 | 3.72 | 3.73 |
| Support 1 (S1) | 3.57 | 3.62 | 3.51 | 3.56 | 3.39 |
| Support 2 (S2) | 3.44 | 3.55 | 3.43 | 3.36 | |
| Support 3 (S3) | 3.28 | 3.44 | 3.34 | ||
| Support 4 (S4) | 3.27 |
